Ardelyx

WKN: A116X0 ISIN: US0396971071 Kürzel: 41X Mehr zu "ARDELYX"

Börse
Lang & Schwarz

6,55 EUR

-6,76 % -0,48

Geld (Stk.) 6,500 (3.549)
Brief (Stk.) 6,600 (3.549)
Spread 1,515
Geh. Stück 1 Stk
Eröffnung 7,025
Vortag 7,025
52 Wochen Hoch 8,175
52 Wochen Tief 1,896

Stand: 25.02.2020 - 17:23:34 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Alles für nur 4 Euro pro Order. Dauerhaft.
Smartbroker

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Frankfurt 6,500 6,650 1582628420 12:00 15 7,10 EUR
Berlin 6,500 6,600 1582639480 15:04 0 7,05 EUR
Düsseldorf 6,500 6,700 1582616894 08:48 0 7,00 EUR
Stuttgart 6,450 6,700 1582638269 14:44 0 6,70 EUR
Nasdaq 7,130 7,150 1582646623 17:03 124.809 7,13 USD
AMEX 0,000 0,000 1582592400 02:00 100 7,65 USD
Tradegate 6,550 6,600 1582643121 16:05 400 6,75 EUR
Lang & Schwarz 6,500 6,600 1582647814 17:23 1 6,55 EUR
BX Swiss 6,962 7,009 01.01.70 0 0,00 CHF

Realtime / Verzögert

Neueste Kommentare (18)

Neu laden

Alle Kommentare Neu laden

Schorsch11

Schorsch11 vom 12.09.19 21:16 Uhr

rdelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation https://www.benzinga.com/pressreleases/19/09/n14424331/ardelyx-receives-fda-approval-for-ibsrela-tenapanor-an-nhe3-sodium-transport-inhibitor-for-the-tre https://seekingalpha.com/article/4291196-ardelyx-advances-drug-chronic-kidney-disease-soc-treatment-lacks

B

Bullethead vom 04.09.19 00:31 Uhr

Tendenz hoffentlich weiter nach oben

S

Stocky1000 vom 03.09.19 22:03 Uhr

Wow hier geht es ab

Schorsch11

Schorsch11 vom 03.09.19 14:41 Uhr

Back YahooFINANCE Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment  PR NewswireSeptember 3, 2019, 2:00 PM GMT+2 The primary and all key secondary endpoints were met. Tenapanor in combination with binders met the primary endpoint demonstrating a statistically significant (p=0.0004) reduction of serum phosphorus compared to binders alone. Approximately two times more patients achieved the established serum phosphorus treatment goal of less than 5.5mg/dL in the tenapanor arm compared to binders alone (p -values≤0.0097) for each week of treatment. https://finance.yahoo.com/news/ardelyx-announces-positive-results-pivotal-120000881.html

Schorsch11

Schorsch11 vom 03.09.19 10:03 Uhr

Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study https://finance.yahoo.com/news/ardelyx-host-conference-call-september-200000222.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAANkKburamt2MoGzIWIKz0iY0LmQIcEbydIrL79nnuKr9peohRpAnysLaqxVCFgFmmEDtffSlmaWxHeitbJ-NSQADMjoknpsuk-vMslm7b16hO4rtMI2cVOC4xAoNYS4ByaGNG75RWZCCjCbgkdZdhBd5ybJz73x6GNB0ROLx91HP

xbi123hdlt

xbi123hdlt vom 27.08.19 16:46 Uhr

wieder +7%

Schorsch11

Schorsch11 vom 27.08.19 09:31 Uhr

Ardelyx: Attractive Valuation, Upcoming Major Catalysts STRENDING PORTFOLIO PEOPLE MARKET NEWS STOCK IDEAS DIVIDENDS INVESTING STRATEGY REITS WALL STREET BREAKFAST ON THE MOVE DIVIDEND NEWS MARKET OUTLOOK  Leonard Yaffe Follow Long Ideas Healthcare  Ardelyx: Attractive Valuation, Upcoming Major Catalysts Aug. 26, 2019 6:56 PM ETArdelyx, Inc. (ARDX)5 Comments1 Like Summary Ardelyx drug, tenapanor, has been studied in two underserved markets that both exceed $1 billion in US revenues, namely IBS-C and hyperphosphatemia in dialysis patients. The FDA PDUFA date for the IBS-C indication is September 12. The company does not yet have a US marketing partner, but a favorable decision should remedy that need. Tenapanor will have data readouts on two Phase 3 studies, PHREEDOM and AMPLIFY, for the hyperphosphatemia indication this year. The drug could be on the US market in 2021. Ardelyx has $124 million in cash, $50 million in long-term debt, and 63 million shares outstanding. The quarterly cash burn rate is in the $20-25 million range. The market capitalization is $240 million. https://seekingalpha.com/article/4288036-ardelyx-attractive-valuation-upcoming-major-catalysts?source=quotemedia_readmore

Alle Kommentare Neu laden

News zu ARDELYX

30.06.2014, 00:00 Uhr
XFRA FRA:New Instruments available on XETRA - 30.06.2014-003

Grundlegende Daten zur ARDELYX Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -

Ardelyx

Börsennotierung

Marktkapitalisierung
444,20 Mio EUR
Anzahl der Aktien
65,81 Mio Stück